SEMA4A and hepatocellular carcinoma: More importantly, a published experiment has suggested that knockdown of Sema4A can improve the EMT process and increase sensitivity to doxorubicin (a chemotherapy agent for treating hepatoma) in hepatoma cells (Pan, Wang & Ye, 2016).